发布求助
文献互助 智能选刊 最新文献

Medicine - Programa de Formación Médica Continuada Acreditado最新文献

筛选
英文 中文
Cáncer de próstata 前列腺癌
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.02.004
N. González García, N. Fernández-Díaz, P. Freijido-Álvarez, C. Fernández-Reino, M. Giráldez-Martínez, J. Ruíz-Bañobre, L. León-Mateos, U. Anido-Herranz
{"title":"Cáncer de próstata","authors":"N. González García,&nbsp;N. Fernández-Díaz,&nbsp;P. Freijido-Álvarez,&nbsp;C. Fernández-Reino,&nbsp;M. Giráldez-Martínez,&nbsp;J. Ruíz-Bañobre,&nbsp;L. León-Mateos,&nbsp;U. Anido-Herranz","doi":"10.1016/j.med.2025.02.004","DOIUrl":"10.1016/j.med.2025.02.004","url":null,"abstract":"<div><div>Prostate cancer is one of the most common neoplasms in men, with a high incidence worldwide and significant mortality. The disease has a variable course; it usually presents in a fulminant manner, although there are cases of rapidly progressing disease with a very poor prognosis. Most tumors are adenocarcinomas. Its etiology is multifactorial, involving genetic, hormonal, and environmental factors. In 5%-10% of cases, it is associated with germline mutations of genes such as <em>BRCA1, BRCA2,</em> and <em>ATM</em>, and it is described within Lynch syndrome. Prostate cancer staging uses the TNM and Gleason systems to define tumor stage and aggressiveness as well as the best treatment strategy to follow. Treatment ranges from active surveillance in low risk cases, radical treatment with radiotherapy or surgery along with androgen deprivation therapy in localized higher risk stages, the use of hormone therapy for palliative purposes in cases of unresectable recurrence or hormone sensitive metastatic disease, or the use of cytotoxic drugs such as taxane-based chemotherapy in cases of metastatic disease refractory to castration. In some specific cases, treatments such as lutetium, radium, PARP inhibitors, or immunotherapy are considered. Close follow-up is key in order to avoid overdiagnosis and overtreatment.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 26","pages":"Pages 1541-1551"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocolo de prevención y diagnóstico precoz de los tumores digestivos II: cáncer de páncreas y colorrectal 消化系统肿瘤预防和早期诊断议定书二：胰腺癌和结肠直肠癌
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.01.017
I. Bartolomé Oterino, S. Redondo Evangelista, P. García Centeno, M. Sierra Morales, I. Gala Moreno, A. Santos Rodríguez, N. Hernanz Ruiz
{"title":"Protocolo de prevención y diagnóstico precoz de los tumores digestivos II: cáncer de páncreas y colorrectal","authors":"I. Bartolomé Oterino,&nbsp;S. Redondo Evangelista,&nbsp;P. García Centeno,&nbsp;M. Sierra Morales,&nbsp;I. Gala Moreno,&nbsp;A. Santos Rodríguez,&nbsp;N. Hernanz Ruiz","doi":"10.1016/j.med.2025.01.017","DOIUrl":"10.1016/j.med.2025.01.017","url":null,"abstract":"<div><div>The incidence of pancreatic and colorectal cancers is increasing globally and causes significant morbidity and mortality in our setting. Diagnosis in early stages is one of the most relevant prognostic factors. Early diagnosis is essential in order to improve the prognosis, which is why screening programs have become of particular interest.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 25","pages":"Pages 1511-1515"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143322442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocolo diagnóstico y terapéutico de la hipercalcemia en el paciente oncológico 癌症患者高钙血症的诊断和治疗方案
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.02.006
N. Fernández-Díaz, P. Freijido-Álvarez, P. Pita-López, U. Anido-Herranz, J. Ruíz-Bañobre, L. León-Mateos, R. López-López
{"title":"Protocolo diagnóstico y terapéutico de la hipercalcemia en el paciente oncológico","authors":"N. Fernández-Díaz,&nbsp;P. Freijido-Álvarez,&nbsp;P. Pita-López,&nbsp;U. Anido-Herranz,&nbsp;J. Ruíz-Bañobre,&nbsp;L. León-Mateos,&nbsp;R. López-López","doi":"10.1016/j.med.2025.02.006","DOIUrl":"10.1016/j.med.2025.02.006","url":null,"abstract":"<div><div>Hypercalcemia is a common and serious complication in patients with cancer, especially in cancers with bone metastases. Symptoms range from mild to severe, such as confusion and muscle weakness. The diagnosis is based on the measurement of calcium levels and differentiation from other causes. Treatment includes hydration, bisphosphonates, or denosumab and, in severe cases, hemodialysis. It is essential to treat the underlying malignancy in order to provide long-term control of hypercalcemia and to improve the patient's quality of life.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 26","pages":"Pages 1557-1561"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocolo de diagnóstico y tratamiento del hepatocarcinoma 肝癌诊断和治疗规程
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.01.014
L. González Sánchez-Ocaña , I. Beceiro Pedreño , D. del Pozo Prieto , R. Molina Villaverde
{"title":"Protocolo de diagnóstico y tratamiento del hepatocarcinoma","authors":"L. González Sánchez-Ocaña ,&nbsp;I. Beceiro Pedreño ,&nbsp;D. del Pozo Prieto ,&nbsp;R. Molina Villaverde","doi":"10.1016/j.med.2025.01.014","DOIUrl":"10.1016/j.med.2025.01.014","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver. It occurs in most cases in patients with liver cirrhosis. Although there has been significant progress in the development of new therapies for HCC in recent years, it continues to be a significant cause of mortality in these patients. Therefore, it is vitally important to comply with screening programs, with biannual ultrasound examination, in an attempt to make the earliest possible diagnosis. Given the peculiarity of this tumor, which in most cases is located on a diseased liver with liver cirrhosis, prognostic classification systems must be used that take into account not only tumor extension but also the situation of the liver disease, such as the <em>Barcelona Clinic Liver Cancer</em> classification system.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 25","pages":"Pages 1495-1500"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143357300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cáncer de vejiga 膀胱癌
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.02.002
P. Pita-López, U. Anido-Herranz, N. Fernández-Díaz, N. González-García, L. León-Mateos, J. Ruíz-Bañobre, R. López-López
{"title":"Cáncer de vejiga","authors":"P. Pita-López,&nbsp;U. Anido-Herranz,&nbsp;N. Fernández-Díaz,&nbsp;N. González-García,&nbsp;L. León-Mateos,&nbsp;J. Ruíz-Bañobre,&nbsp;R. López-López","doi":"10.1016/j.med.2025.02.002","DOIUrl":"10.1016/j.med.2025.02.002","url":null,"abstract":"<div><div>Bladder cancer is the ninth most frequent neoplasm in the world and the fifth in Europe. It usually occurs at older ages, with peak incidence between 70 and 80 years of age. The most common risk factor is smoking, which accounts for 50% of the cases. Bladder cancer usually presents with asymptomatic hematuria. This hematuria should be studied with a proper screening with cystoscopy and cytology. It may also be necessary to perform a computed tomography (CT) scan or to enlarge the tract to be analyzed. Treatment will take into account the degree of local involvement and distance. If the disease is local and there is no involvement of the bladder muscle layer, treatment will be based on a transurethral resection (TUR) with or without additional instillations depending on the risk of recurrence. If there is muscular layer involvement, treatment will be based on a radical cystectomy accompanied by neoadjuvant or adjuvant chemotherapeutic treatment. Finally, if there is distant metastatic disease, treatment will be based on chemotherapy and immunotherapy.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 26","pages":"Pages 1528-1533"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocolo diagnóstico y terapéutico del carcinoma de la vía biliar 胆道癌的诊断和治疗方案
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.01.015
R. Molina Villaverde , B. Martínez-Amores , A. López Alfonso , A.M. Jiménez Gordo
{"title":"Protocolo diagnóstico y terapéutico del carcinoma de la vía biliar","authors":"R. Molina Villaverde ,&nbsp;B. Martínez-Amores ,&nbsp;A. López Alfonso ,&nbsp;A.M. Jiménez Gordo","doi":"10.1016/j.med.2025.01.015","DOIUrl":"10.1016/j.med.2025.01.015","url":null,"abstract":"<div><div>Bile duct cancer encompasses a heterogeneous group of epithelial neoplasms originating in the biliary tree, including the gallbladder. It is considered a rare tumor in Western countries, although its incidence has increased in recent years. There are different anatomical subgroups with differences in risk factors, clinical presentation, molecular characteristics, and locoregional treatments. Most cases will be diagnosed in advanced stages and there will be recurrence in up to 80% of resected tumors, so they are neoplasms with a poor prognosis.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 25","pages":"Pages 1501-1505"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143322443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarcadores moleculares y celulares en los tumores genitourinarios, implicaciones terapéuticas 泌尿生殖肿瘤的分子和细胞生物标志物，治疗意义
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.02.008
C. Fernández-Reino, N. Fernández-Díaz, N. González-García, M. Giráldez-Martínez, U. Anido-Herranz, P. Freijido-Álvarez, J. Ruíz-Bañobre, L. León-Mateos.
{"title":"Biomarcadores moleculares y celulares en los tumores genitourinarios, implicaciones terapéuticas","authors":"C. Fernández-Reino,&nbsp;N. Fernández-Díaz,&nbsp;N. González-García,&nbsp;M. Giráldez-Martínez,&nbsp;U. Anido-Herranz,&nbsp;P. Freijido-Álvarez,&nbsp;J. Ruíz-Bañobre,&nbsp;L. León-Mateos.","doi":"10.1016/j.med.2025.02.008","DOIUrl":"10.1016/j.med.2025.02.008","url":null,"abstract":"<div><div>A biomarker is a measurable characteristic that provides information about a biological or pathological state or a response to a treatment. Predictive biomarkers inform us about the probability of response to a specific treatment. As oncology moves towards tumor molecular characterization and histology becomes less important, biomarkers are gaining importance in therapeutic decision making. This protocol summarizes the main recommendations regarding the determination of these markers in genitourinary tumors and their therapeutic implications.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 26","pages":"Pages 1566-1569"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cáncer renal 肾脏癌症
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.02.001
P. Freijido Álvarez, C. Fernández-Reino, N. González-García, U. Anido-Herranz, J. Ruíz-Bañobre, L. León-Mateos, R. López-López
{"title":"Cáncer renal","authors":"P. Freijido Álvarez,&nbsp;C. Fernández-Reino,&nbsp;N. González-García,&nbsp;U. Anido-Herranz,&nbsp;J. Ruíz-Bañobre,&nbsp;L. León-Mateos,&nbsp;R. López-López","doi":"10.1016/j.med.2025.02.001","DOIUrl":"10.1016/j.med.2025.02.001","url":null,"abstract":"<div><div>Kidney cancer ranks 14<sup>th</sup> among the most common neoplasms. It is more frequent in Europe and North America. Renal cell carcinoma is the predominant subtype, accounting for 90% of cases, followed by papillary carcinoma. The diagnosis is made by CT scan. Treatment varies according to the disease stage and can range from surgery to combination therapies. Immunological therapy has shown improved outcomes, especially in patients with a medium-high risk level.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 26","pages":"Pages 1523-1527"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actualización del cáncer de esófago 食道癌更新
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.01.010
A.M. Jiménez Gordo , E. Casado Saenz , I. Hernández de Córdoba Sánchez , R. Molina Villaverde
{"title":"Actualización del cáncer de esófago","authors":"A.M. Jiménez Gordo ,&nbsp;E. Casado Saenz ,&nbsp;I. Hernández de Córdoba Sánchez ,&nbsp;R. Molina Villaverde","doi":"10.1016/j.med.2025.01.010","DOIUrl":"10.1016/j.med.2025.01.010","url":null,"abstract":"<div><div>Esophageal cancer is the sixth leading cause of mortality due to cancer in the world. The epidermoid histologic type is the most frequent and is mainly related to toxic habits. It usually occurs in the proximal and middle third and produces extensive local and lymph node infiltration. Adenocarcinoma is more frequent in the distal esophageal third and gastroesophageal junction (GEJ). Its incidence is increasing in Western society, especially in younger patients, and it is associated with obesity and gastroesophageal reflux. The management of this neoplasm requires adequate staging and a multidisciplinary assessment that includes surgical, radiotherapeutic, and systemic treatment. Surgery is the mainstay in localized tumors of the middle and inferior third. Locally advanced cases may benefit from chemoradiotherapy. In disseminated stages, different determinations are important, such as HER2 status, microsatellite instability, mutational load, and immune activation. This allows for individualizing treatment, the pillar of which continues to be chemotherapy, and improving the prognosis of patients with this disease.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 25","pages":"Pages 1459-1468"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143357302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tratamiento del carcinoma renal, a propósito de un caso 肾癌的治疗，针对一个病例
Medicine - Programa de Formación Médica Continuada Acreditado Pub Date : 2025-02-01 DOI: 10.1016/j.med.2025.02.009
J.M. Abuelo-Rey, P. Pardo-Guzmán, U. Anido-Herranz, L. León-Mateos, R. López-López
{"title":"Tratamiento del carcinoma renal, a propósito de un caso","authors":"J.M. Abuelo-Rey,&nbsp;P. Pardo-Guzmán,&nbsp;U. Anido-Herranz,&nbsp;L. León-Mateos,&nbsp;R. López-López","doi":"10.1016/j.med.2025.02.009","DOIUrl":"10.1016/j.med.2025.02.009","url":null,"abstract":"","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 26","pages":"Pages 1570.e1-1570.e3"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信